GSK has entered into a partnership with Chinese pharmaceutical outfit Hengrui Pharma to jointly develop up to 12 medicines, in a deal that could be worth up to $12bn.

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the drugmakers said on Monday.